77882 Federal Register / Vol. 75, No. 239 / Tuesday, December 14, 2010 / Notices 

information collection that has been 

extended, revised, or implemented on or 

after October 1, 1995 unless it displays 

a currently valid OMB control number. 

Proposed Collection 

Title: Recruitment and Screening for 

the Insight into Determination of 

Exceptional Aging and Longevity 

(IDEAL) Study. Type of Information 

Collection Request: NEW. Need and Use 

of Information Collection: The purpose 

of the project is to conduct recruitment 

and screening for the IDEAL Study. A 

multifaceted recruitment approach will 

be used to reach the target audience in 

a wide variety of ways. Those who are 

interested in participating in the IDEAL 

study will be asked to complete a two 

stage recruitment process consisting of a 

telephone interview and a physical 

exam. The Stage One interview consists 

of questions concerning demographics, 

physical ability, health status, and 

medical conditions. Those who are 

eligible after completing the telephone 

interview will be asked to complete the 

second stage of the screening process. 

The physical examination is a modified 

version of the full BLSA assessment 

protocol consisting of the following 

components: General appearance; vital 

signs; chest and heart auscultation; 

sensory systems including vision, 

hearing, sensory proprioception, 

neuropathy and balance; and movement 

and strength of the upper and lower 

extremities. In addition the potential 

participant will also be asked to 

complete physical performance tests, 

cognitive exams, an electrocardiogram 

and a blood draw. Frequency of 

Response: Once. Affected Public: 

Individuals or households. Type of 

Respondents: Healthy individuals who 

are at least 80 years of age. The annual 

reporting burden is as follows: 

Estimated Number of Respondents: 

1,500; Estimated Number of Responses 

per Respondent: 1; Average Burden 

Hours per Response: 0.833; and 

Estimated Total Annual Burden Hours 

Requested: 701. There is no annualized 

cost to respondents. There are no 

Capital costs to report. There are no 

Operating or Maintenance Costs to 

report. 

Type of respondent Number of 

respondents 

Frequency of 

response 

Average time 

per response 

Annual hour 

burden 

Individuals who complete the phone interview .............................................. 1,500 1 0 .167 251 

Individuals who complete the physical exam ................................................ *300 1 1 .5 450 

Totals .................................................................................................. 1,500 ........................ .......................... 701 

*These individuals are included in the 1,500 above. 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the function of the 

agency, including whether the 

information will have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) Ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

Ways to minimize the burden of the 

collection of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Direct Comments to OMB: Written 

comments and or suggestions regarding 

the item(s) contained in the notice, 

especially regarding the estimated 

public burden and associated response 

time should be directed to the: Office of 

Management and Budget, Office of 

Regulatory Affairs, OIRA 

submission@omb.eop.gov or by fax to 

202–395–6974. Attention: Desk Officer 

for NIH. To request more information on 

the proposed project or obtain a copy of 

the data collection plans and 

instruments, contact Dr. Luigi Ferrucci, 

Principal Investigator, NIA Clinical 

Research Branch, Harbor Hospital, 5th 

Floor, 3001 S. Hanover, Baltimore, MD 

21225, or call this non-toll-free number 

(410) 350–3936 or E-mail your request 

including your address to: 

Ferruccilu@grc.nia.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30-days of the date of 

this publication. 

Dated: December 6, 2010. 

Melissa Fraczkowski, 

Project Clearance Liaison, NIA. 

[FR Doc. 2010–31376 Filed 12–13–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Software System for Quantitative 

Assessment of Vasculature in Three 

Dimensional Images 

Description of Invention: This 

invention offered for licensing and 

further development is a software 

system that provides the capability of 

efficiently extracting, visualizing and 

quantifying three dimensional vascular 

networks from medical and basic 

research images. Deregulation of 

angiogenesis plays a major role in a 

number of human diseases, most 

notably cancer. A substantial increase in 

the research effort in this field over the 

past decade has deepened the 

understanding of the angiogenic 

process. However, the lack of methods 

and software to quantitatively assess 

vasculature in patients has considerably 

hampered the ability to directly study 

the angiogenesis process, as well as to 

discover and develop new therapeutics 

to modulate angiogenesis. The present 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 75, No. 239 / Tuesday, December 14, 2010 / Notices 77883 

invention provides new semi-automated 

computer algorithms, statistical 

methods and user friendly visualization 

tools for rapid and intuitive quantitative 

evaluation of vasculature in three 

dimensional data sets obtained through 

non-invasive imaging techniques such 

as MRI, CT–Scans, confocal microscopy, 

microCT, etc. The methods and software 

embodied in this invention provide a 

three dimensional quantitative 

capability in the clinic as a vascular 

diagnostic tool and in basic research 

projects to evaluate changes in vascular 

network systems. 

Applications: 

• Medical research for studying 

angiogenesis and tumor vasculature. 

• Potential applications in clinical 

studies and diagnostics. 

• Discovery and development of antiangiogenesis agents with application to 

cancer. 

• Possible application to diseases 

other than cancer, such as those related 

to the lymphatic system, the pulmonary 

airway, the kidney filtration system. 

Development Status: 

• The invention is fully developed. 

• The software will be readily 

available if so requested. 

Inventors: Enrique Zudaire, 

Christopher Kurcz, Yanling Liu (NCI). 

Patent Status: HHS Reference No. E– 

261–2010/0—Software. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for 

licensing. 

Licensing Contacts: 

• Uri Reichman, PhD, MBA; 301– 

435–4616; UR7a@nih.gov. 

• Michael Shmilovich, Esq.; 301– 

435–5019; ShmilovichM@mail.nih.gov. 

Compounds That Treat Malaria and 

Prevent Malaria Transmission 

Technology Summary: The invention 

offered for licensing relates to 

therapeutic compounds and related 

pharmaceutical compositions that can 

be used in the prevention and treatment 

of malaria infection. More specifically, 

the invention is drawn to compounds 

that can kill malaria gametocytes to 

block malaria transmission and treat 

malaria infection in the non-erthtrocytic 

stages, as well as therapeutic uses of 

these molecules to prevent or slow the 

transmission of plasmodium organisms 

between mammals and eliminate or 

prevent infection in mammal. 

Furthermore, the compounds of the 

invention are tricyclic compounds 

where the side rings may be 5–7 

membered rings (preferably 6- 

membered), and the center ring may be 

6–8 membered ring (preferably 7- 

membered). Also preferable structures 

are ones in which the side rings are aryl 

rings while the center ring is cycloalkyl 

ring. The compounds of the invention 

have been identified by integrating 

quantitative high-throughput screening 

(qHTS) with genetic mapping and in 

vivo oocyst formation assay. 

Applications: Prevention and 

treatment of malaria infections. 

Inventors: Xin-zhuan Su and Jing 

Yuan (NIAID). 

Patent Status: International Patent 

Application No. PCT/US2010/047019 

filed August 27, 2010. Priority 

Application 61/237,417 filed August 27, 

2009. (HHS Reference No. E–283–2009). 

Licensing Status: Available for 

licensing. 

Licensing Contacts: 

• Uri Reichman, PhD, MBA; 301– 

435–4616; UR7a@nih.gov. 

• Michael Shmilovich, Esq.; 301– 

435–5019; ShmilovichM@mail.nih.gov. 

A Universal Antigen Delivery Platform 

for Enhanced Immune Response 

Description of Invention: The present 

invention relates to use of the rotavirus 

NSP2 octamer as a universal antigen 

delivery platform for presenting a high 

density of neutralizing epitopes to the 

immune system, a strategy for boosting 

antigen immunogenicity. This 

application is advanced by the welldefined structural and biochemical 

properties of the octamer, its high 

stability at a broad range of pH, 

temperature and ionic stability, and its 

ease of purification (one step) under 

nondenaturing conditions. Long 

conformationally-dependent antigens 

are readily mounted onto the platform 

by fusion to the C-terminus of NSP2, a 

region of the NSP2 protein positioned 

on the exposed surface of the octamer. 

The platform can be expressed in and 

purified from prokaryotic and 

eukaryotic systems. 

This technology can be used for rapid 

production of subunit vaccines against a 

wide range of infectious agents. 

Additional uses of the technology 

include the generation of delivery 

platforms with mounted short peptide 

antigens for use in cancer 

immunotherapy, production of specific 

antisera to conformationally and 

nonconformationally-dependent 

antigens for research purposes, and 

development of epitope targets and 

short peptide-antigen presentation 

platforms for diagnostic assays. 

Applications: 

• Vaccines against pathogens. 

• Cancer vaccines. 

• Antigen-specific antisera. 

• Multivalent targets in diagnostic 

assays. 

Advantages: 

• Octameric platform is stable, 

efficiently expressed, and easily 

purified by a single step method. 

• Enables the display of multivalent 

conformation-dependent epitopes. 

• Effective platform for short peptides 

as well as long polypeptides. 

Development Status: Proof-of-concept 

experiments have shown that the 

octamer mounted with short peptides or 

long multivalent polypeptides retains its 

structural and biophysical features and 

is highly effective in presenting foreign 

antigens to the immune system. Ease of 

purification and final protein yields of 

the short or long peptide antigenmounted NSP2 octamers were 

comparable suggesting that the platform 

accommodates a large range of antigen 

sizes. The NSP2-platform also served as 

an adjuvant, significantly enhancing 

immunity of the mounted peptide. 

Inventors: John T. Patton (NIAID); 

Zenobia F. Taraporewala (NIAID). 

Relevant Publications: 

1. P Schuck et al. Rotavirus 

nonstructural protein NSP2 selfassembles into octamers that undergo 

ligand-induced conformational changes. 

J Biol Chem. 2001 Mar 30;276(13):9679– 

9687. [PubMed: 11121414]. 

2. H Jayaram et al. Rotavirus protein 

involved in genome replication and 

packaging exhibits a HIT-like fold. 

Nature. 2002 May 16;417(6886):311– 

315. [PubMed: 12015608]. 

3. Z Taraporewala et al. Rotavirus 

NSP2 octamer as an epitope-mounting 

platform. Abstract, 23rd Annual 

Meeting of the American Society for 

Virology, 2004. 

4. K Kearney et al. Cell-line-induced 

mutation of the rotavirus genome alters 

expression of an IRF3-interacting 

protein. EMBO J. 2004 Oct 

13;23(20):4072–4081. [PubMed: 

15372078]. 

Patent Status: U.S. Patent Application 

No. 11/293,654 filed 02 Dec 2005 (HHS 

Reference No. E–322–2004/0–US–02). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Kevin W. Chang, 

PhD; 301–435–5018; 

changke@mail.nih.gov. 

Dated: December 1, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–30640 Filed 12–13–10; 8:45 am] 

BILLING CODE 4140–01–P 


srobinson on DSKHWCL6B1PROD with NOTICES